Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OKd & More
Summary
Company news slowed somewhat this week, perhaps as some took the federal Martin Luther King Jr. Day holiday away from the office and others recovered from back-to-back meetings and late nights at the JP Morgan Healthcare Conference. —Halozyme Therapeutics (NASDAQ: HALO), a San Diego company that closed its oncology operations late last year, said it ex[ects its Enhanze drug-delivery technology business will bring it to profitability in the second quarter of 2020. —The FDA also awarded accelerated approval to tazemetostat (Tazverik), an Epizyme (NASDAQ: EPZM) drug developed to treat the rare soft tissue cancer epithelioid sarcoma. —CEOs of women’s health companies at the JP Morgan Healthcare Conference talked with Xconomy about their struggle to raise funds to advance novel products in the sector—and their hope for a coming revitalization of the space. —Amsterdam-based iOnctura, a 2017 spinoff of Merck KGaA, reported raising a €15 million Series A, financing round to advance its lead program into a Phase 1 trial in solid tumors and another through preclinical studies.
Classifications
AskAI Classifications
LabelsLinked Companies
